Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
Tesamorelin reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
Tesamorelin is a synthetic growth hormone-releasing hormone analogue, stabilised. Based on endogenous growth hormone-releasing hormone.
Reported to mimic the hypothalamic GHRH signal, prompting pituitary growth hormone release in a pulsatile pattern. Vectra makes no claim as to mechanism or effect.
An FDA-approved product containing this moiety exists, approved November 2010 for one narrow indication under its own labelling. A research-use reference material is not that product, and that product’s data does not characterise it.
Evaluated in Phase 3 trials for excess visceral abdominal fat in HIV-positive patients with lipodystrophy, and approved by FDA in November 2010.
Studied in visceral adipose tissue reduction and the growth hormone axis. Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
Approved for one narrow indication on Phase 3 evidence. That evidence characterises the approved product in that population — not this material, and not any other use.
Our sources carry no CAS number, formula, molecular weight, sequence, residue count, safety data, or storage data for Tesamorelin.
An approved product containing this moiety exists (November 2010). This material is supplied for in-vitro research use only. No therapeutic, preventive, or diagnostic claims are made or implied.
Yes — in more than one way:
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.
Compatibility does not assert current availability. No preparation, ratio, or protocol guidance renders here.